Relation of body mass index to on-treatment (clopidogrel + aspirin) platelet reactivity.
Gaglia, MA, Torguson, R, Pakala, R, Xue, Z, Sardi, G, Mahmoudi, M, Suddath, WO, Kent, KM, Satler, LF, Pichard, AD and Waksman, R (2011) Relation of body mass index to on-treatment (clopidogrel + aspirin) platelet reactivity. Am J Cardiol, 108 (6). pp. 766-771.
Full text not available from this repository.Abstract
Previous research has suggested that obesity is associated with increased high on-treatment platelet reactivity. We therefore tested platelet reactivity in 251 patients with VerifyNow P2Y12, vasodilator-stimulated phosphoprotein phosphorylation, and light transmission aggregometry with adenosine diphosphate 5 and 20 μM 6 to 24 hours after percutaneous coronary intervention. High on-treatment platelet reactivity was defined as a maximum platelet aggregation ≥46% for light transmission aggregometry with adenosine diphosphate 5 μM or ≥60% for 20 μM, platelet reactivity index ≥50% for vasodilator-stimulated phosphoprotein phosphorylation, and P2Y12 reaction units ≥235 for VerifyNow. The relation between body mass index (BMI) and platelet reactivity values was examined with Spearman coefficients; BMI and high on-treatment platelet reactivity were assessed with Student's t test. Multivariable logistic regression for high on-treatment platelet reactivity was also performed. Average BMI was 30.3 ± 5.9 kg/m² and 44% of patients had a BMI ≥30 kg/m². Overall there was very poor correlation between BMI and on-treatment platelet reactivity, with Spearman coefficients ranging from 0.08 to 0.10. BMI was also not associated with the various definitions of high on-treatment platelet reactivity. Multivariable logistic regressions showed no association between BMI and high on-treatment platelet reactivity. In conclusion, and contrary to previous reports, we found no association whatsoever between BMI and on-treatment platelet reactivity as quantified by a variety of platelet function tests.
Item Type: | Article | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Divisions : | Surrey research (other units) | ||||||||||||||||||||||||||||||||||||
Authors : |
|
||||||||||||||||||||||||||||||||||||
Date : | 15 September 2011 | ||||||||||||||||||||||||||||||||||||
DOI : | 10.1016/j.amjcard.2011.04.029 | ||||||||||||||||||||||||||||||||||||
Uncontrolled Keywords : | Adenosine Diphosphate, Aspirin, Body Mass Index, Cell Adhesion Molecules, Coronary Disease, Female, Humans, Logistic Models, Male, Microfilament Proteins, Middle Aged, Phosphoproteins, Platelet Aggregation, Platelet Function Tests, Risk Factors, Statistics, Nonparametric, Ticlopidine | ||||||||||||||||||||||||||||||||||||
Depositing User : | Symplectic Elements | ||||||||||||||||||||||||||||||||||||
Date Deposited : | 17 May 2017 09:47 | ||||||||||||||||||||||||||||||||||||
Last Modified : | 24 Jan 2020 17:38 | ||||||||||||||||||||||||||||||||||||
URI: | http://epubs.surrey.ac.uk/id/eprint/825100 |
Actions (login required)
![]() |
View Item |
Downloads
Downloads per month over past year